Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

NCT06869239 · clinicaltrials.gov ↗

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Interventions

DRUG: Etoposide + cisplatin/carboplatin
RADIATION: Thoracic radiotherapy
RADIATION: Prophylactic cranial irradiation (PCI)
DRUG: PD-L1 inhibitor

Sponsor

Peking University Cancer Hospital & Institute